Химиотерапия второй линии у больных диссеминированным раком желудка
Диссертация
Несмотря на снижение заболеваемости раком желудка в России на протяжении последних двух десятков лет, он продолжает уверенно занимать второе место, как по показателям заболеваемости, так и смертности среди всех злокачественных новообразований. В большинстве случаев рак желудка диагностируется уже в поздних стадиях. В России в 2006 г лишь у 23,3% больных заболевание было выявлено на I-II стадиях… Читать ещё >
Содержание
- Список сокращений
- ГЛАВА 1. Обзор литературы
- 1. 1. Первая линия химиотерапии метастатического рака желудка
- 1. 2. Вторая линия химиогератш метастатического рака желудка
- 1. 3. Прогностические и предсказывающие факторы эффективности второй линии химиотерапии при лечении метастатического рака желудка
- ГЛАВА 2. Материалы и методы и исследования
- ГЛАВА 3. Результаты исследования
- 3. 1. Характеристики больных, получивших одну линию и две линии химиотерапии
- 3. 2. Характеристики больных на момент начала второй линии химиотерапии
- 3. 3. Эффективность различных режимов второй линии химиотерапии
- 3. 4. Изучение режима biMMC во второй линии химиотерапии
- 3. 5. Однофакгорный анализ показателей, влияющих на общую выживаемость при второй линии химиотерапии
- 3. 6. Многофакторный регрессионный анализ Кокса дня выживаемости
- 3. 7. Прогностическая модель
- 3. 8. Токсичность режима ЫММСво второй линии химиотерапии
- ГЛАВА 4. Обсуждение
Список литературы
- Давыдов М.И., Аксель Е. М. Статистика злокачественных новообразований в России и странах СНГ в 2006 г. // Вестник Российского онкологического научного центра имени Н. Н. Блохина РАМН. № 2, том 19, 2008.
- Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002 cancer incidence, mortality and prevalence worldwide. IARC cancerbase no. 5, version 2.0. Lyon: IARC Press- 2004.
- World Health Organization. The World Health Report 2003. Geneva: WHO- 2003.
- Correa P, Chen VW. Gastric cancer. Cancer Surv 1994- 19−20:55−76.
- Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003−56:1−9.
- Powell J, McConkey CC. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer 1990−62:440−3.
- Verdecchia A, Corazziari I, Gatta, et al. Explaining gastric cancer survival differences among European countries. Int J Cancer 2004−109:737−41.
- Fielding JWL, Powell J, Allum WH. Cancer of the stomach. London: The Macmillan Press- 1989.
- Hoichi Kato. Cancer Statistics in Japan, 2008.
- Гарин A.M., Базин И. С. Злокачественные опухоли пищеварительной системы. М.: Инфомедиа Паблишерз, 2003.
- F Berrino, R De Angelis, М Sant, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995−99: results of the EUROCARE-4 study. Lancet Oncol 2007: 8: 773−783.
- Catalano V, et al. Gastric cancer. Crit Rev Oncol/Hematol (2009), doi: 10.1016/j .critrevonc.2009.01.004.
- Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006−24:2903−9.
- Murad AM, Santiago FF, Petroianu A, et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993−72:37−41.
- Pyrhonen S, Kuitunen T, Nyandoto P, et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with nonresectable gastric cancer. Br J Cancer 1995−71:587−91.
- Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997−8:163−8.
- Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997−15:261−7.
- Kelsen D, Atiq ОТ, Saltz L, et al. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992−10:541−8.
- Kim NK, Park YS, Heo DS, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin С versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993−71:3813−8.
- Cocconi G, Carlini P, Gamboni A, et al. Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. Ann Oncol 2003−14:1258−63.
- Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008−358:36−46.
- Atsushi Ohtsu. Chemotheapy for metastatic gastric cancer: past, present, and future. J Gastroenterol 2008- 43:256−264.
- Van Cutsem E, Haller D, Ohtsu A: The role of chemotherapy in the current treatment of gastric cancer. Gastric Cancer 2002, 5(Suppl 1): 17−22.
- C.A. Тюляндин. Химиотерапия рака желудка. Практическая Онкология № 7 (сентябрь) 2001 г. стр. 44−55.
- Lacave AJ, Wils J, Diaz-Rubio E, et al. Cisplatinum as second-line chemotherapy in advanced gastric adenocarcinoma. A phase II study of the EORTC Gastrointestinal Tract Cancer Cooperative Group Eur J Cancer Clin Oncol 1985−21:1321−1324.
- Ohtsu A, Yoshida S, Saito D- et al. An early phase II study of 5-fluorouracil combined with cisplatinum as a second-line chemotherapy against metastatic gastric cancer. Jpn J Clin Oncol 1991−21:120−124.
- Vanhoeffer U, Wilke H, Weh HJ, et al. Weekly high dose 5-fluorouracil and folinic acid as salvage treatment in advanced gastric cancer. Ann Oncol 1994−5:850−851.
- Lee JL, Ryu MH, Chang HM, et al. A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy. Cancer Chemother Pharmacol 2008−61:631−7.
- Nguyen S, Rebischung C, Van Ongeval J, et al. Epirubicin-docetaxel in advanced gastric cancer: two phase II studies as second and first line treatment. Bull Cancer 2006−93:El-6.
- Rosati G, Bilancia D, Germano D, et al. Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients withmetastatic gastric cancer: a phase II study. Ann Oncol 2007−18(Suppl. 6):vi28−32.
- Barone C, Basso M, Schinzari G, et al. Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer. Gastric Cancer 2007−10:104−11.
- Park SH, Kang WK, Lee HR, et al. Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen. Am J Clin Oncol 2004−27:477−80.
- Kunisaki C, Imada T, Yamada R, et al. Phase II study of docetaxel plus cisplatin as a second-line combined therapy in patients with advanced gastric carcinoma. Anticancer Res 2005−25:2973−7.
- Polyzos A, Tsavaris N, Kosmas C, et al. Subset of patients with advanced gastric cancer responding to second-line chemotherapy with docetaxel-cisplatin. Anticancer Res 2006−26:3749−53.
- Cascinu S, Graziano F, Cardarelli N, et al. Phase II study of paclitaxel in pre-treated advanced gastric cancer. Anticancer Drugs 1998−9:307−310.
- Hironaka S, Zenda S, Boku N, Fukutomi A, Yoshino T, Onozawa Y. Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 2006−9:14−8.
- Kodera Y, Ito S, Mochizuki Y, et al. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study). Anticancer Res 2007−27:2667−71.
- Arai W, Hosoya Y, Hyodo M, et al. Doxifluridine combined with weekly paclitaxel for second-line treatment in patients with gastric cancer resistant to TS-1. Int J Clin Oncol 2007−12:146−9.
- Stathopoulos GP, Rigatos SK, Fountzilas G, Polyzos A, Stathopoulos JG. Paclitaxel and carboplatin in pre-treated advanced gastric cancer: a phase II study. Oncol Rep 2002−9:89−92.
- Shin SJ, Chun SH, Kim КО, et al. The efficacy of paclitaxel and cisplatin combination chemotherapy for the treatment of metastatic or recurrent gastric cancer: a multicenter phase II study. Korean J Int Med 2005−20:135−40.
- Lee KW, Kim JH, Yun T, et al. Phase II study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer. J Korean Med Sci 2007-(Suppl.22):S115−21.
- Chun JH, Kim HR, Lee JS, et al. Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Jpn J Clin Oncol 2004−34:8−13.
- Shimada S, Yagi Y, Kuramoto M, et al. Second-line chemotherapy with combined irinotecan and low-dose cisplatin for patients with metastatic gastric carcinoma resistant to 5-Fluorouracil. Oncol Rep 2003−10:687−691.
- Baek JH, Kim JG, Sohn SK, et al. Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: a multicenter phase II study. J Korean Med Sci 2005−20:966−70.
- Park SH, Choi EY, Bang SM, et al. Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes. Anticancer Drugs 2005−16:621−5.
- Ueda S, Hironaka S, Boku N, et al. Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer. Gastric Cancer 2006−9:203−7.
- Kim ST, Kang WK, Kang JH, et al. Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer. Br J Cancer 2005−92: 1850−4.
- Assersohn L, Brown G, Cunningham D, et al. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 2004−15:64−9.
- Giuliani F, Molica S, Maiello E, et al. Irinotecan (Iri) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell’Italia Meridionale (prot.2106). Am J Clin Oncol 2005−28:581−5.
- Hartmann JT, Quietsch D, Daikeler T, et al. Mitomycin С continuous infusion as salvage chemotherapy in pre-treated patients with advanced gastric cancer. Anticancer Drugs 1999−10:729−733.
- Ono A, Boku N, Onozawa Y, et al. Activity of S-l in Advanced or Recurrent Gastric Cancer Patients after Failure of Prior Chemotherapy, Including Irinotecan + Cisplatin or Fluorouracil (Except S-l). Jpn J Clin Oncol 2009 39(5):332−335.
- Schmitz SH, Voliotis DL, Schimke J, et al. Continuous 5-fluorouracil and leucovorin as a second-line therapy for advanced gastric carcinoma. Oncology 1994−51:502−506.
- Barone C, Cassano A, Landriscina M, et al. Bolus and infusional 5-fluorouracil combined with cisplatin in advanced gastric cancer. Oncol Rep 2000−7:1305−1309.
- Catalano V, Graziano F, Santini D, et al. Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? Br J Can 2008−99, 1402−1407.
- Ji SH, Lim DH, Yi SY, et al. A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer. BMC Cancer 2009- 9:110 doi:10.1186/1471−2407−9-110
- Yoshida M, Ohtsu A, Boku N, et al. Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. Jpn J Clin Oncol 2004−34: 654−659.
- Lee J, Lim T, Uhm JE, Park KW, et al. Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol 2007−18: 886−891.
- Park SH, Lee J, Lee SH, et al.: Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol 2006, 57(l):91−96.
- Andreyev HJ, Norman AR, Oates J, et al: Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 1998−34:503−509.
- Wilke H, Preusser P, Stahl M, et al. Etoposide, folinic acid, and 5-fluorouracil in carboplatin pre-treated patients with advanced gastric cancer. Cancer Chemother Pharmacol 1991−29:83−84.